Aquinox Pharmaceutic (AQXP) 8.35 $AQXP Aquinox to

New Post Public Reply Private Reply Replies (0) Message Board

Aug 1, 2016 at 9:13 AM

Aquinox Pharmaceutic (AQXP) 8.35 $AQXP

Aquinox to Present at Jefferies 2016 Healthcare Conference
GlobeNewswire - Wed Jun 01, 8:15AM CDT
Aquinox Pharmaceuticals, Inc. ("Aquinox"

(NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, is pleased to announce the appointment of Mrs. Abigail L. Jenkins as Chief Commercial Officer and Mr. Paul Brennan as Vice President, Business Development. Mrs. Jenkins will act as our US Business Head at our San Bruno, CA office and lead the design and implementation of the commercialization strategy for AQX-1125 while Mr. Brennan will be responsible for the identification and fostering of corporate alliances to support and compliment our global business strategies.
ACT: 298.98 (-2.94), AQXP: 8.35 (+0.03), PFE: 37.04 (+0.15)

Aquinox to Present at 2016 Annual UBS Global Healthcare Conference
GlobeNewswire - Wed May 18, 8:15AM CDT
Aquinox Pharmaceuticals, Inc. ("Aquinox"

(NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today provided a corporate update and reported financial results for the first quarter ending March 31, 2016.
AQXP: 8.35 (+0.03)

Aquinox to Present at 2016 Bloom Burton & Co. Healthcare Investor Conference
GlobeNewswire - Thu Apr 28, 8:16AM CDT
Aquinox Pharmaceuticals, Inc. ("Aquinox"

(NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main, Aquinox President & CEO, will present a corporate overview at the upcoming 15 Annual Needham Healthcare Conference in New York city on Wednesday, April 13, 2016 at 12:10 PM Eastern Time.
AQXP: 8.35 (+0.03)

Aquinox Pharmaceuticals Announces Year End 2015 Financial Results
GlobeNewswire - Mon Mar 14, 6:17PM CDT
-- Advancing to first Phase 3 trial for AQX-1125 in IC/BPS
AQXP: 8.35 (+0.03)

Dermatologists Praise Multiple Benefits of Oculus Innovative Science's Microcyn Technology
ACCESSWIRE - Tue Mar 08, 8:29AM CST
REDONDO BEACH, CA / ACCESSWIRE / March 8, 2016 / Right now there is hypochlorous acid, or HOCl, on the immunological front lines in the bodies of people fighting infections, doing its job as an inorganic bactericidal compound of the innate immune system to destroy a wide spectrum of pathogens. Although still not used as a pharmaceutical drug, the important role of hypochlorous acid in biology is only recently emerging, in addition to its well-documented germicidal properties. For example, research by Serhan Sakarya, MD, et al. shows that HOCl in stable form is an ideal wound care solution with a powerful and rapid killing effect on different types of microorganisms, biofilms and microbicidal effect within the biofilm.
AQXP: 8.35 (+0.03), VNDA: 11.40 (-0.10), VTAE: 10.65 (-0.40), OCLS: 4.29 (-0.45)

Global Asthma Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/wdlwml/asthma_pipeline) has announced the addition of the "Asthma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Asthma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Asthma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Asthma Overview - Therapeutics Development - Pipeline Products for Asthma - Overview - Pipeline Products for Asthma - Comparative Analysis - Asthma - Therapeutics under Development by Companies - Asthma - Therapeutics under Investigation by Universities/Institutes - Asthma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Asthma - Products under Development by Companies - Asthma - Products under Investigation by Universities/Institutes - Asthma - Companies Involved in Therapeutics Development Companies Featured - Partial List - 4D Pharma Plc - AB Science SA - Abeome Corporation - Accolade Pharma LLC - Acorda Therapeutics, Inc. - Adamis Pharmaceuticals Corporation - Advinus Therapeutics Ltd. - Afferent Pharmaceuticals, Inc. - AFFiRiS AG - Alba Therapeutics Corporation - ALK-Abello A/S - Allergopharma GmbH & Co. KG - Amakem NV - Amgen Inc. - AnaptysBio, Inc. - Antisense Therapeutics Limited - Aquinox Pharmaceuticals Inc. - ARA Healthcare Pvt. Ltd. - Ario Pharma Ltd - Array BioPharma Inc. - Aslan Pharmaceuticals Pte. Ltd. - Astellas Pharma Inc. - AstraZeneca Plc - Asubio Pharma Co., Ltd. - Aurigene Discovery Technologies Limited - Axikin Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Biokine Therapeutics Ltd. - BioLineRx, Ltd. - Bioncotech Therapeutics S.L. - Biotec Pharmacon ASA - BioTech Tools s.a. - Boehringer Ingelheim GmbH - Caladrius Biosciences, Inc. - CalciMedica, Inc. For more information visit http://www.researchandmarkets.com/research/wd...a_pipeline
AQXP: 8.35 (+0.03), ADMP: 2.81 (unch), AMGN: 172.20 (+0.17), ACOR: 25.28 (+0.33), CLBS: 5.54 (+0.08), AZN: 33.61 (-0.53), ARRY: 3.74 (-0.03)

Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review - Companies Mentioned Include Afferent Pharmaceuticals, Allergan Plc & Qu Biologics Inc
M2 - Fri Jan 29, 2:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/bv59zp/interstitial) has announced the addition of the "Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Afferent Pharmaceuticals, Inc. - Allergan Plc - Aquinox Pharmaceuticals Inc. - Kytogenics Pharmaceuticals, Inc. - Lipella Pharmaceuticals, Inc. - MediPost Co., Ltd. - Qu Biologics Inc. - Urigen Pharmaceuticals, Inc. Key Topics Covered: - Introduction - Interstitial Cystitis (Painful Bladder Syndrome) Overview - Therapeutics Development - Pipeline Products for Interstitial Cystitis (Painful Bladder Syndrome) - Overview - Pipeline Products for Interstitial Cystitis (Painful Bladder Syndrome) - Comparative Analysis - Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics under Development by Companies - Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics under Investigation by Universities/Institutes - Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Interstitial Cystitis (Painful Bladder Syndrome) - Products under Development by Companies - Interstitial Cystitis (Painful Bladder Syndrome) - Products under Investigation by Universities/Institutes - Interstitial Cystitis (Painful Bladder Syndrome) - Companies Involved in Therapeutics Development Companies Mentioned: - Afferent Pharmaceuticals, Inc. - Allergan Plc - Aquinox Pharmaceuticals Inc. - Kytogenics Pharmaceuticals, Inc. - Lipella Pharmaceuticals, Inc. - MediPost Co., Ltd. - Qu Biologics Inc. - Urigen Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/bv...terstitial
AGN: 253.90 (+0.95), AQXP: 8.35 (+0.03)

Aquinox to Present at LEERINK Partners 5th Annual Global Healthcare Conference
GlobeNewswire - Thu Jan 28, 8:15AM CST
Aquinox Pharmaceuticals, Inc. ("Aquinox"

(NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today announced receipt of official minutes from its December 8, 2015 meeting with the Division of Bone, Reproductive and Urologic Products (DBRUP) of the United States Food and Drug Administration (FDA) and provided an update on its plans for development of AQX-1125 for the treatment of patients with bladder pain syndrome/interstitial cystitis (BPS/IC). Discussed at the meeting were guidance and recommendations regarding proposed pivotal trial designs with AQX-1125 for BPS/IC, as well as additional supportive clinical, preclinical and manufacturing activities that could potentially be required for registration.
AQXP: 8.35 (+0.03)

Innovation Sparks Advancement of New Treatments for Atopic Dermatitis
ACCESSWIRE - Thu Jan 07, 8:25AM CST
REDONDO BEACH, CA / ACCESSWIRE / January 7, 2016 / Even though the root cause of atopic dermatitis (AD), or eczema, remains a mystery, this is an exciting time in the dermatology space with innovation driving substantial advancements for the first time in decades. As Peter Lio, MD, assistant professor of clinical dermatology and pediatrics-dermatology at Northwestern University Feinberg School of Medicine, explained in the October edition of The Dermatologist, part of the challenge rests in the fact that a range of factors play a role in the immunopathogenesis of AD, a chronic, itchy inflammation of the skin that can range from mild to severe.
AQXP: 8.35 (+0.03), VNDA: 11.40 (-0.10), VTAE: 10.65 (-0.40), OCLS: 4.29 (-0.45)

Aquinox Pharmaceuticals Announces Appointment of Ms. Shelley McCloskey as Vice President, Human Resources & Administration
GlobeNewswire - Tue Dec 22, 8:15AM CST
Aquinox Pharmaceuticals, Inc. ("Aquinox"

(NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, is pleased to announce the appointment of Ms. Shelley McCloskey as Vice President of Human Resources & Administration. Ms. McCloskey has joined the Executive team to help guide the continued growth and development of the Company.
AQXP: 8.35 (+0.03)

Aquinox Selected for Addition to NASDAQ Biotechnology Index
GlobeNewswire - Wed Dec 16, 8:15AM CST
Aquinox Pharmaceuticals, Inc. ("Aquinox"

(NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today announced that it has been selected for addition to the NASDAQ Biotechnology Index effective prior to market open on Monday, December 21, 2015.
AQXP: 8.35 (+0.03)

Non-Alcoholic Steatohepatitis Therapeutics Pipeline Review 2015
M2 - Fri Dec 11, 8:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/gd4hqf/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlbireoPharma - Aquinox Pharmaceuticals Inc. - Ardelyx, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Connexios Life Sciences Pvt. Ltd. - Daiichi Sankyo Company, Limited - Dr. Falk Pharma GmbH - DURECT Corporation - Dynavax Technologies Corporation - Enanta Pharmaceuticals, Inc. - Exicure, Inc. - Galectin Therapeutics, Inc. - Galmed International Ltd. - Genfit SA - GenKyoTex S.A. - Gilead Sciences, Inc. - iCo Therapeutics Inc. - Merck & Co., Inc. - Mochida Pharmaceutical Co., Ltd. - NGM Biopharmaceuticals, Inc. - Nimbus Therapeutics, LLC - Nippon Chemiphar Co., Ltd. - Novartis AG - Novo Nordisk A/S - Protalix BioTherapeutics, Inc. - Regulus Therapeutics Inc. - RuiYi Inc. - Shire Plc - Vascular Biogenics Ltd. - Verva Pharmaceuticals Limited - Viking Therapeutics, Inc. - Virobay Inc. - Zafgen Inc. - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/gd...nalcoholic
DVAX: 15.43 (-0.07), ZFGN: 3.05 (+0.01), AQXP: 8.35 (+0.03), GALT: 1.64 (+0.07), RGLS: 3.57 (unch), BMY: 75.31 (+0.50), DRRX: 1.94 (+0.08), ENTA: 22.49 (+1.49), NVO: 57.31 (+0.34), GILD: 79.50 (+0.03), SHPG: 194.18 (+0.06), MRK: 58.66 (unch), VBAY: (), VBLT: 4.02 (unch), VKTX: 1.40 (-0.06), NVS: 83.26 (+1.18)

Aquinox to Participate in Two Upcoming Investor Events
GlobeNewswire - Thu Dec 10, 8:15AM CST
Aquinox Pharmaceuticals, Inc. ("Aquinox"

(NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today announced that senior management will be meeting with investors at two upcoming investor events.
AQXP: 8.35 (+0.03)

Beyond the Chart, What Price Data Reveals - Research on Endochoice Holdings, Catalyst Pharmaceuticals, Aquinox Pharmaceuticals and ARC Document Solutions
ACCESSWIRE - Thu Nov 19, 7:45AM CST
NEW YORK, NY / ACCESSWIRE / November 19, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Endochoice Holdings Inc. (NYSE: GI), Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), Aquinox Pharmaceuticals Inc. (NASDAQ: AQXP) and ARC Document Solutions Inc. (NYSE: ARC). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
ARC: 4.00 (+0.06), AQXP: 8.35 (+0.03), CPRX: 0.72 (unch), GI: 5.33 (-0.30)

Newer

Older